Unison Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Unison Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,422	Closed	-$921K	–	199
2023 Q1	$921K	Hold	25,422	–	–	0.1%	85
2022 Q4	$907K	Hold	25,422	–	–	0.12%	84
2022 Q3	$861K	Buy	25,422 +5,935	+30%	+$193K	0.16%	80
2022 Q2	$563K	Hold	19,487	–	–	0.15%	91
2022 Q1	$630K	Hold	19,487	–	–	0.15%	88
2021 Q4	$568K	Hold	19,487	–	–	0.14%	96
2021 Q3	$519K	Hold	19,487	–	–	0.13%	91
2021 Q2	$600K	Hold	19,487	–	–	0.11%	85
2021 Q1	$510K	Hold	19,487	–	–	0.1%	90
2020 Q4	$491K	Buy	+19,487	New	+$419K	0.11%	79

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Unison Advisors's SUPN Position: Q2 2023 in Review

Unison Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2023, closing a stake of 25,422 shares — an estimated $921K sold.

Unison Advisors first reported a position in SUPN in Q4 2020 and held it in 10 quarters. The position peaked at $921K in Q1 2023. 249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.

Unison Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Unison Advisors sold 25,422 Supernus Pharmaceuticals shares in Q2 2023, an estimated $921K.
Unison Advisors first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 10 quarters.
Unison Advisors's Supernus Pharmaceuticals position peaked at $921K in Q1 2023.
249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.

Based on Unison Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.